Carlyle and SK Capital to take gene therapy firm bluebird bio private
The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, bluebird stockholders will receive $3 per share in cash.
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform rating on the shares ...
New York State Teachers Retirement System trimmed its position in The Carlyle Group Inc. (NASDAQ:CG – Free Report) by 0.7% during the 4th quarter, HoldingsChannel reports. The firm owned 44,246 shares ...
Shares of Carlyle-backed Hexaware Technologies rose as much as 10% in their debut on Wednesday, indicating rising retail interest in India's first billion-dollar IPO that struggled to achieve full ...
Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...
The Carlyle Group has acquired a controlling stake in two India-based auto component manufacturers, Highway Industries Limited and Roop Automotives Limited. Carlyle is merging both to form an auto ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback